

Severe Acute Respiratory Syndrome (SARS) Therapeutics Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/SBF03F6DC620EN.html>

Date: March 2022

Pages: 65

Price: US\$ 3,250.00 (Single User License)

ID: SBF03F6DC620EN

Abstracts

This report contains market size and forecasts of Severe Acute Respiratory Syndrome (SARS) Therapeutics in Global, including the following market information:

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Severe Acute Respiratory Syndrome (SARS) Therapeutics market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

CEL-1000 Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Severe Acute Respiratory Syndrome (SARS) Therapeutics include CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals, Inc., Nanotherapeutics, Inc., Novavax, Inc., Phelix Therapeutics, LLC and Protein Sciences Corporation, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Severe Acute Respiratory Syndrome (SARS) Therapeutics companies, and industry experts on this industry,

involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Segment Percentages, by Type, 2021 (%)

CEL-1000

D-3252

FDX-000

INO-4500

LCA-60

Others

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Research Center

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Severe Acute Respiratory Syndrome (SARS) Therapeutics revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Severe Acute Respiratory Syndrome (SARS) Therapeutics revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

CEL-SCI Corporation

GeneCure LLC

Humabs BioMed SA

Inovio Pharmaceuticals, Inc.

Nanotherapeutics, Inc.

Novavax, Inc.

Phelix Therapeutics, LLC

Protein Sciences Corporation

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL SEVERE ACUTE RESPIRATORY SYNDROME (SARS) THERAPEUTICS OVERALL MARKET SIZE

- 2.1 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size: 2021 VS 2028
- 2.2 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Severe Acute Respiratory Syndrome (SARS) Therapeutics Players in Global Market
- 3.2 Top Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Companies Ranked by Revenue
- 3.3 Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Companies
- 3.4 Top 3 and Top 5 Severe Acute Respiratory Syndrome (SARS) Therapeutics Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Severe Acute Respiratory Syndrome (SARS) Therapeutics

Product Type

3.6 Tier 1, Tier 2 and Tier 3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Players in Global Market

3.6.1 List of Global Tier 1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Companies

3.6.2 List of Global Tier 2 and Tier 3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size Markets, 2021 & 2028

4.1.2 CEL-1000

4.1.3 D-3252

4.1.4 FDX-000

4.1.5 INO-4500

4.1.6 LCA-60

4.1.7 Others

4.2 By Type - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue & Forecasts

4.2.1 By Type - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, 2017-2022

4.2.2 By Type - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, 2023-2028

4.2.3 By Type - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.1.4 Research Center

5.2 By Application - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue & Forecasts

5.2.1 By Application - Global Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue, 2017-2022

5.2.2 By Application - Global Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue, 2023-2028

5.2.3 By Application - Global Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2021 & 2028

6.2 By Region - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue & Forecasts

6.2.1 By Region - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, 2017-2022

6.2.2 By Region - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, 2023-2028

6.2.3 By Region - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, 2017-2028

6.3.2 US Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.3.3 Canada Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.3.4 Mexico Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, 2017-2028

6.4.2 Germany Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.4.3 France Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.4.4 U.K. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.4.5 Italy Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.4.6 Russia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size,

2017-2028

6.4.7 Nordic Countries Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.4.8 Benelux Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, 2017-2028

6.5.2 China Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.5.3 Japan Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.5.4 South Korea Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.5.5 Southeast Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.5.6 India Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, 2017-2028

6.6.2 Brazil Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.6.3 Argentina Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, 2017-2028

6.7.2 Turkey Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.7.3 Israel Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.7.4 Saudi Arabia Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

6.7.5 UAE Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 CEL-SCI Corporation

7.1.1 CEL-SCI Corporation Corporate Summary

7.1.2 CEL-SCI Corporation Business Overview

7.1.3 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Major Product Offerings

7.1.4 CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in Global Market (2017-2022)

7.1.5 CEL-SCI Corporation Key News

7.2 GeneCure LLC

7.2.1 GeneCure LLC Corporate Summary

7.2.2 GeneCure LLC Business Overview

7.2.3 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Major Product Offerings

7.2.4 GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in Global Market (2017-2022)

7.2.5 GeneCure LLC Key News

7.3 Humabs BioMed SA

7.3.1 Humabs BioMed SA Corporate Summary

7.3.2 Humabs BioMed SA Business Overview

7.3.3 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Major Product Offerings

7.3.4 Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in Global Market (2017-2022)

7.3.5 Humabs BioMed SA Key News

7.4 Inovio Pharmaceuticals, Inc.

7.4.1 Inovio Pharmaceuticals, Inc. Corporate Summary

7.4.2 Inovio Pharmaceuticals, Inc. Business Overview

7.4.3 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Major Product Offerings

7.4.4 Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in Global Market (2017-2022)

7.4.5 Inovio Pharmaceuticals, Inc. Key News

7.5 Nanotherapeutics, Inc.

7.5.1 Nanotherapeutics, Inc. Corporate Summary

7.5.2 Nanotherapeutics, Inc. Business Overview

7.5.3 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Major Product Offerings

7.5.4 Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in Global Market (2017-2022)

7.5.5 Nanotherapeutics, Inc. Key News

7.6 Novavax, Inc.

7.6.1 Novavax, Inc. Corporate Summary

7.6.2 Novavax, Inc. Business Overview

7.6.3 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Major Product Offerings

7.6.4 Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in Global Market (2017-2022)

7.6.5 Novavax, Inc. Key News

7.7 Phelix Therapeutics, LLC

7.7.1 Phelix Therapeutics, LLC Corporate Summary

7.7.2 Phelix Therapeutics, LLC Business Overview

7.7.3 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Major Product Offerings

7.7.4 Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in Global Market (2017-2022)

7.7.5 Phelix Therapeutics, LLC Key News

7.8 Protein Sciences Corporation

7.8.1 Protein Sciences Corporation Corporate Summary

7.8.2 Protein Sciences Corporation Business Overview

7.8.3 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Major Product Offerings

7.8.4 Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in Global Market (2017-2022)

7.8.5 Protein Sciences Corporation Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Opportunities & Trends in Global Market

Table 2. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Drivers in Global Market

Table 3. Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Restraints in Global Market

Table 4. Key Players of Severe Acute Respiratory Syndrome (SARS) Therapeutics in Global Market

Table 5. Top Severe Acute Respiratory Syndrome (SARS) Therapeutics Players in Global Market, Ranking by Revenue (2021)

Table 6. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue by Companies, (US\$, Mn), 2017-2022

Table 7. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Share by Companies, 2017-2022

Table 8. Global Companies Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Type

Table 9. List of Global Tier 1 Severe Acute Respiratory Syndrome (SARS) Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 10. List of Global Tier 2 and Tier 3 Severe Acute Respiratory Syndrome (SARS) Therapeutics Companies, Revenue (US\$, Mn) in 2021 and Market Share

Table 11. By Type – Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 12. By Type - Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 13. By Type - Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 14. By Application – Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 15. By Application - Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in Global (US\$, Mn), 2017-2022

Table 16. By Application - Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in Global (US\$, Mn), 2023-2028

Table 17. By Region – Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2021 & 2028

Table 18. By Region - Global Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue (US\$, Mn), 2017-2022

Table 19. By Region - Global Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue (US\$, Mn), 2023-2028

Table 20. By Country - North America Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2023-2028

Table 30. CEL-SCI Corporation Corporate Summary

Table 31. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Offerings

Table 32. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 33. GeneCure LLC Corporate Summary

Table 34. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Offerings

Table 35. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 36. Humabs BioMed SA Corporate Summary

Table 37. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Offerings

Table 38. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 39. Inovio Pharmaceuticals, Inc. Corporate Summary

Table 40. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Offerings

Table 41. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 42. Nanotherapeutics, Inc. Corporate Summary

Table 43. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Offerings

Table 44. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 45. Novavax, Inc. Corporate Summary

Table 46. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Offerings

Table 47. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 48. Phelix Therapeutics, LLC Corporate Summary

Table 49. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Offerings

Table 50. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US\$, Mn), (2017-2022)

Table 51. Protein Sciences Corporation Corporate Summary

Table 52. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Product Offerings

Table 53. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

Figure 1. Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Type in 2021

Figure 2. Severe Acute Respiratory Syndrome (SARS) Therapeutics Segment by Application in 2021

Figure 3. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Overview: 2021

Figure 4. Key Caveats

Figure 5. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size: 2021 VS 2028 (US\$, Mn)

Figure 6. Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, 2017-2028 (US\$, Mn)

Figure 7. The Top 3 and 5 Players Market Share by Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue in 2021

Figure 8. By Type - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share, 2017-2028

Figure 9. By Application - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share, 2017-2028

Figure 10. By Region - Global Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share, 2017-2028

Figure 11. By Country - North America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share, 2017-2028

Figure 12. US Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 13. Canada Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 14. Mexico Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 15. By Country - Europe Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share, 2017-2028

Figure 16. Germany Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 17. France Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 18. U.K. Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 19. Italy Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 20. Russia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 21. Nordic Countries Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 22. Benelux Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 23. By Region - Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share, 2017-2028

Figure 24. China Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 28. India Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share, 2017-2028

Figure 30. Brazil Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Market Share, 2017-2028

Figure 33. Turkey Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue, (US\$, Mn), 2017-2028

Figure 37. CEL-SCI Corporation Severe Acute Respiratory Syndrome (SARS) Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. GeneCure LLC Severe Acute Respiratory Syndrome (SARS) Therapeutics

Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Humabs BioMed SA Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Inovio Pharmaceuticals, Inc. Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Nanotherapeutics, Inc. Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Novavax, Inc. Severe Acute Respiratory Syndrome (SARS) Therapeutics

Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. Phelix Therapeutics, LLC Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Protein Sciences Corporation Severe Acute Respiratory Syndrome (SARS)

Therapeutics Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Severe Acute Respiratory Syndrome (SARS) Therapeutics Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/SBF03F6DC620EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SBF03F6DC620EN.html>